samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > dendritic cells for cancer immunotherapy
PUBLICATIONS
European Biopharmaceutical Review

Dendritic Cells for Cancer Immunotherapy

Cancer is one of the major killers in the developed world, accounting for over one million deaths in North America and Europe annually. In the US, the annual incidence of cancer is approximately 1,200,000, and the number of people dying of the disease each year is about 500,000 (1). The American Cancer Society estimates that one in three Americans will develop cancer in his or her lifetime. Between 1970 and 1990, the overall five-year survival rate of treated cancer patients improved by about 10 per cent as a result of earlier detection, improved radio- and chemotherapies and, possibly, changes in living habits. However, with the exception of small cell lung carcinoma and breast cancer, improvement in advanced stages has been negligible. Moreover, the lack of specificity of radio- and chemotherapies causes severe side effects. Therefore, new therapies with better efficacy and specificity are needed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Jean-Pierre Abastado, Vice-President, Scientific Affairs, IDM

Jean-Pierre Abastado is Vice-President in charge of Scientific Affairs at IDM. He is on leave from the CNRS, where he is Research Director. He graduated from the Ecole Polytechnique in 1978 and obtained his PhD in biological sciences from the University of Paris VI in 1986. From 1979 to 1998, he held several positions at the Pasteur Institute (in Paris, France) and NIH (in Bethesda, US). From 1990 to 1998, he managed a group of eight people in the unit of Professor Philippe Kourilsky, specialising in molecular biology and fundamental immunology. Between 1994 and 1998 he was named, on several occasions, an independent expert by the Pasteur Institute, Pasteur-Mérieux Sérums et Vaccins and INSERM. He is the Author of more than 80 scientific publications and of several patent applications in France and the US.

spacer
Jean-Pierre Abastado
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Fresenius Kabi modernises production facility in France

Fresenius Kabi is investing about €35 million to modernise the company’s production facility in Louviers, France. Two sterilisation units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernisation is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement